Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.80 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.67 |
| ▸ | GSK3A | P49840 | 1/20 | 0.67 |
| ▸ | MAPK15 | Q8TD08 | 1/20 | 0.67 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21846968 | 1.00 | EGFR (1.00) | EGFRALKLRRK2GSK3AMAPK15 | |
| SCHEMBL16752965 | 0.89 | ALK (1.00) | EGFRALK | |
| SCHEMBL21846999 | 0.89 | EGFR (1.00) | EGFRALKLRRK2 | |
| SCHEMBL21847025 | 0.85 | EGFR (1.00) | EGFRALK | |
| SCHEMBL26612049 | 0.85 | ALK (0.75) | EGFRALK | |
| SCHEMBL16752944 | 0.83 | ALK (1.00) | ALK | |
| SCHEMBL16752967 | 0.83 | ALK (1.00) | ALK | |
| SCHEMBL21847004 | 0.82 | EGFR (1.00) | EGFRLRRK2 | |
| SCHEMBL30936860 | 0.82 | EGFR (1.00) | EGFRLRRK2 | |
| SCHEMBL17530379 | 0.82 | ALK (0.82) | EGFRALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249482-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249482-A1 | N2,N4-DIPHENYLPYRIMIDINE-2,4-DIAMINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF CANCER | FLT3, EGFR, ERBB2 | EGFR 2/4885ALK 76/4885LRRK2 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.